Lancet Regional Health-Europe最新文献

{"title":"Prioritising meaningful outcomes in the practice evaluation of new chlamydia testing guidelines","authors":"Zoïe W. Alexiou , Nicole H.T.M. Dukers-Muijrers","doi":"10.1016/j.lanepe.2025.101579","DOIUrl":"10.1016/j.lanepe.2025.101579","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101579"},"PeriodicalIF":13.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Parkinson's disease psychosis—a European perspective","authors":"Walter Pirker ,&nbsp;Joaquim J. Ferreira ,&nbsp;Olivier Rascol ,&nbsp;Werner Poewe","doi":"10.1016/j.lanepe.2025.101569","DOIUrl":"10.1016/j.lanepe.2025.101569","url":null,"abstract":"<div><div>Hallucinations and delusions are among the most disabling long-term complications of Parkinson's disease (PD). Their pathogenesis is based on a complex interaction of neurodegeneration in critical areas for visual and cognitive processing and PD medication effects. Management rests on the identification and treatment of acute triggers, simplification of PD medication and treatment with antipsychotics. Despite the high prevalence of psychosis in advanced PD there is still a lack of familiarity with its manifestations and therapeutic approaches. This gap is further enhanced by recent developments in drug availability and therapeutic monitoring. Pimavanserin is the only approved drug for the treatment of PD psychosis in the U.S., but currently not marketed elsewhere. The aim of this review is to provide an update on the management options for PD psychosis in other regions of the world with a focus on clinical practice in Europe. Quetiapine and clozapine remain cornerstones of treatment of PD psychosis in Europe. Despite limited evidence for efficacy, quetiapine is often used as first-line therapy, whereas severe PD psychosis usually requires treatment with clozapine, with clozapine demonstrating efficacy without worsening of motor symptoms in randomised, controlled trials. Other antipsychotics should be avoided in PD psychosis due to their ineffectiveness or high potential for worsening parkinsonian motor symptoms. Novel drugs with a better risk-benefit ratio in the treatment of PD psychosis are needed. Non-pharmacological treatments should be explored in relation to their potential to prevent or mitigate psychotic reactions in prospective studies.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"62 ","pages":"Article 101569"},"PeriodicalIF":13.0,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5 years of the Lancet Regional Health – Europe: science, equity, and why Europe must lead","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2025.101588","DOIUrl":"10.1016/j.lanepe.2025.101588","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"60 ","pages":"Article 101588"},"PeriodicalIF":13.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary endpoint acceptance is strongly associated with a positive benefit assessment: a self-fulfilling prophecy","authors":"Charalabos-Markos Dintsios","doi":"10.1016/j.lanepe.2025.101577","DOIUrl":"10.1016/j.lanepe.2025.101577","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101577"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study","authors":"Rafael Cardoso ,&nbsp;Idris Ola ,&nbsp;Lina Jansen ,&nbsp;Monika Hackl ,&nbsp;Petra Ihle ,&nbsp;Julie Francart ,&nbsp;Nancy Van Damme ,&nbsp;Zdravka Valerianova ,&nbsp;Trayan Atanasov ,&nbsp;Ondřej Májek ,&nbsp;Ondřej Ngo ,&nbsp;Kaire Innos ,&nbsp;Margit Mägi ,&nbsp;Sandrine Dabakuyo Yonli ,&nbsp;Anne-Sophie Woronoff ,&nbsp;Brigitte Tretarre ,&nbsp;Florence Poncet ,&nbsp;Alexander Katalinic ,&nbsp;Paul M. Walsh ,&nbsp;Ieva Vincerževskienė ,&nbsp;Hermann Brenner","doi":"10.1016/j.lanepe.2025.101574","DOIUrl":"10.1016/j.lanepe.2025.101574","url":null,"abstract":"<div><h3>Background</h3><div>Mammography screening programmes have been widely implemented across European countries over the past 40 years with the main aim to detect breast cancer earlier and thereby reduce breast cancer mortality. This study aimed to analyse and compare changes over time in breast cancer incidence, by stage at diagnosis, and breast cancer mortality across countries in relation to the timing of screening implementation and age at diagnosis.</div></div><div><h3>Methods</h3><div>In this population-based study conducted in 21 European countries, data from cancer registries covering over 3 million female patients diagnosed with breast cancer, along with data from national statistical offices from 1978 to 2019 were analysed. Annual age-standardised breast cancer incidence rates (by stage and age at diagnosis) and age-standardised breast cancer mortality rates were calculated. Average annual percent changes (AAPCs) in these metrics within 10 years before and 10 years after screening implementation were estimated.</div></div><div><h3>Findings</h3><div>Overall, breast cancer incidence rates increased over the study period, with the largest increases observed in the first two decades (1978–1987 and 1988–1997), and AAPCs of up to 4.55 (95% confidence interval, CI, 2.56–6.57). In contrast, breast cancer mortality rates decreased most predominantly in the last two decades (1998–2007 and 2008–2018/19), with AAPCs down to −5.40 (95% CI, −9.70 to −0.89). The largest increases in incidence were seen for in situ and stage I cancers (AAPCs ranging from non-significant to 12.03 (95% CI, 7.40–16.86) following screening implementation). Incidence of stage IV cancer declined or remained stable in most countries, with AAPCs down to −6.16 (95% CI, −8.28 to −4.00) after screening introduction. These trends were particularly pronounced among age groups targeted by screening (mostly 50–69 years). Breast cancer mortality rates declined by up to 3 percent annually after screening initiation (lowest AAPC estimate −3.29 (95% CI, −6.26 to −0.23); yet, AAPCs as low as −2.54 (95% CI, −3.15 to −1.93) were also observed before introduction of screening programmes in countries where implementation occurred later, in the 2000s.</div></div><div><h3>Interpretation</h3><div>This study suggests that mammography screening has influenced trends in breast cancer incidence and mortality in European countries. The results point to the contribution of mammography screening, alongside advances in diagnostics and treatment, to the observed reductions in breast cancer mortality.</div></div><div><h3>Funding</h3><div>There was no funding source for this study.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"62 ","pages":"Article 101574"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial","authors":"Georgios Tavoulareas ,&nbsp;Olga Kontakou-Zoniou ,&nbsp;Nikolaos Antonakos ,&nbsp;Elisavet Tasouli ,&nbsp;George Adamis ,&nbsp;Nikolaos Kakavoulis ,&nbsp;Evangelos Michelakis ,&nbsp;Ilias Skopelitis ,&nbsp;Konstantina Dakou ,&nbsp;Christos Psarrakis ,&nbsp;Panagiotis Koufargyris ,&nbsp;Myrto Astriti ,&nbsp;Styliani Sympardi ,&nbsp;Evangelos J. Giamarellos-Bourboulis","doi":"10.1016/j.lanepe.2025.101573","DOIUrl":"10.1016/j.lanepe.2025.101573","url":null,"abstract":"<div><h3>Background</h3><div>Early recognition of risk of death in pneumonia and start of precision immunotherapy to improve outcomes is an unmet need. We hypothesized that a precision strategy approach combining early recognition of interleukin (IL)-1 activation coupled with Anakinra treatment may improve pneumonia outcome.</div></div><div><h3>Methods</h3><div>INSPIRE is a prospective, double-blind randomized placebo-controlled trial which recruited hospitalized adults with community-acquired or hospital-acquired pneumonia, with qSOFA (quick sequential organ failure assessment) equal to 1 and plasma presepsin (soluble CD14) more than 350 pg/ml. Patients were 1:1 randomised to standard-of-care medication plus either subcutaneous placebo or subcutaneous Anakinra 100 mg once daily for 10 days. The primary endpoint was progression into organ dysfunction defined as meeting at least one of the following two conditions; (i) at least 2-point increase of the baseline SOFA score by day 7 and/or (ii) death by day 90. This was analyzed in the intention-to-treat (ITT) population. This trial is registered with the EU Clinical Trials Register (2022-002390-28) and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (<span><span>NCT05785442</span><svg><path></path></svg></span>).</div></div><div><h3>Findings</h3><div>Patients were enrolled between March 2023 and June 2024; 30 patients in the placebo arm and 30 patients in the Anakinra arm were the ITT population. The primary endpoint was met in 50·0% (15 patients) of placebo-treated and in 20·0% (6 patients) of Anakinra-treated patients (difference 30·0% [5·9 to 49%]; p: 0·011). 90-day mortality was 43·3% (13 patients) and 20·0% (6 patients) (difference 23·3% [0 to 43·7%]; p: 0·029). The overall incidence of serious treatment-emergent adverse events (TEAEs) in the placebo group was 50% and in the Anakinra group 33·3%. None of the serious TEAEs was judged to be related to treatment assignment. Production of TNFα and ΙFNγ by blood mononuclear cells was decreased.</div></div><div><h3>Interpretation</h3><div>Presepsin-guided Anakinra treatment prevents progression of pneumonia to organ dysfunction and death. The mechanism of benefit is associated with attenuation of cytokine production.</div></div><div><h3>Funding</h3><div><span>Hellenic Institute for the Study of Sepsis</span>; <span>PHC Europe BV</span>; <span>Swedish Orphan Biovitrum AB</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"62 ","pages":"Article 101573"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to coronary angiography and revascularization in 575,247 patients with STEMI from 2012 to 2023: a retrospective population-based cohort study","authors":"Paulina E. Stürzebecher ,&nbsp;Ulrich Laufs ,&nbsp;Philip Baum ,&nbsp;Johannes Diers ,&nbsp;Armin Wiegering ,&nbsp;Konstantin Uttinger","doi":"10.1016/j.lanepe.2025.101576","DOIUrl":"10.1016/j.lanepe.2025.101576","url":null,"abstract":"<div><h3>Background</h3><div>Rapid primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI) reduces in-hospital and long-term mortality. This study analyzes time intervals to PPCI in STEMI, risk factors for delay of PPCI, and in-hospital mortality from 2012 to 2023.</div></div><div><h3>Methods</h3><div>This is a retrospective population-based analysis of hospital billing data of adult STEMI patients receiving PPCI in Germany. The time for transport to hospital (TTH) was estimated using geographic routing. The in-hospital time to angiography (IHTA) was calculated using time coding of PPCI in patient records.</div></div><div><h3>Findings</h3><div>A total of 575,247 patients were included. The median age was 64 years, 28.5% (164,016) were female. The population with IHTA ≤60 min increased from 44.5% (22,240/49,965) in 2012 to 57.7% (24,434/42,356) in 2023 with improved TTH + IHTA ≤120 min (56.6%, 28,280/49,965, in 2012–70.2%, 29,734/42,356, in 2023). IHTA improved from median 73.1 min (IQR 25.2–186.6) in 2012 to 46.4 min (IQR 17.5–111.6) in 2023 with a stable TTH (11.4–11.9 min). Risk factors for an IHTA &gt;60 min included age, female sex, comorbidity, presentation out of regular hours, and low-volume hospitals. In-hospital mortality increased (8.8%, 4406/49,965, in 2012, 10.4%, 4822/46,203, in 2021, 10.1%, 4272/42,356, in 2023), paralleling a rise in patient age and comorbidity. Risk factors for in-hospital mortality included female sex, increased age, comorbidity, high-volume hospitals, intervention of multiple coronary arteries, weekend admission, and presentation out of regular hours. IHTA &lt;40 min (90–120 min as reference) and TTH + IHTA &lt;80 min (≥120 min as reference) reduced the risk of death.</div></div><div><h3>Interpretation</h3><div>Combining hospital billing records with geographic routing enables benchmarking of both pre- and in-hospital delays in STEMI care. In hospital delay decreased between 2012 and 2023. Important areas for improving time delays and STEMI-related mortality include the timeliness of care outside of regular hours and a focus on women, older patients, as well as individuals with comorbidities.</div></div><div><h3>Funding</h3><div>There was no funding for this project or this publication.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"62 ","pages":"Article 101576"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parental wealth and mental disorders in Norway (2006–2023): a nationwide registry-based study of 1.4 million young people","authors":"Joakim Coleman Ebeltoft ,&nbsp;Eivind Ystrøm ,&nbsp;Ziada Ayorech ,&nbsp;Espen Moen Eilertsen","doi":"10.1016/j.lanepe.2025.101567","DOIUrl":"10.1016/j.lanepe.2025.101567","url":null,"abstract":"<div><h3>Background</h3><div>Young people from families with low socioeconomic position have higher rates of mental disorders. However, wealth is underexamined despite large wealth inequity worldwide. Here, we aim to investigate the relationship between early life parental wealth and mental disorders in young Norwegians.</div></div><div><h3>Methods</h3><div>We conducted a population study of associations between early-life parental wealth and 17 diagnostic categories of mental disorders in 1.4 M children (7–12), adolescents (13–18), and young adults (19–24) observed 2006–2023. Ranked parental socioeconomic indicators at age 0–6 (wealth, income, occupation, and education) and mental disorder diagnoses (ICD-10 and ICPC-2) were obtained from Norwegian Tax, Employment, Education, and Control and Payment of Health Reimbursements registries. Estimates were derived from mean prevalences, generalised estimating equations, and sibling comparison designs.</div></div><div><h3>Findings</h3><div>Parental wealth represents a gradient in young people's mental disorders across age, sex, diagnostic categories, and cohorts. The lowest wealth quintile demonstrated 87% [95% CI = 78–96%] higher 1-year prevalence than the highest quintile. In multivariable analyses, parental wealth was the strongest predictor of mental disorders relative risk in adolescents (1.83 [1.76–1.9]) and young adults (1.92 [1.8–2.04]), while wealth (1.53 [1.46–1.6]) and education (1.52 [1.45–1.6]) were the strongest predictors in children. Parental wealth has a significant within-family association with mental disorders (relative risks: children 1.57 [1.44–1.71], adolescents 1.34 [1.26–1.42], young adults 1.42 [1.31–1.54]).</div></div><div><h3>Interpretation</h3><div>Our study serves as a point of reference for understanding the relationship between parental wealth and mental health. Our findings establish early life parental wealth as a fundamental social gradient in young people's mental disorders.</div></div><div><h3>Funding</h3><div><span>European Research Council</span> consolidator grant (#<span><span>101045526</span></span>).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"62 ","pages":"Article 101567"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of welfare regimes on socioeconomic inequalities in edentulism: a cross-national analysis of 40 countries","authors":"Roger Keller Celeste ,&nbsp;Carol Guarnizo-Herreño ,&nbsp;Johan Fritzell ,&nbsp;Francine S. Costa ,&nbsp;Olalekan Ayo-Yusuf ,&nbsp;Aluisio J. Barros ,&nbsp;Huihua Li ,&nbsp;Ninuk Hariyani ,&nbsp;Donna M. Hackley ,&nbsp;Silvana Blanco ,&nbsp;Jorge A. Gamonal ,&nbsp;Gerardo Maupome ,&nbsp;Richard G. Watt ,&nbsp;Marco Aurelio Peres","doi":"10.1016/j.lanepe.2025.101578","DOIUrl":"10.1016/j.lanepe.2025.101578","url":null,"abstract":"<div><h3>Background</h3><div>We aim to evaluate the association between welfare regimes and edentulism (total tooth loss) and to investigate whether welfare regimes modify the magnitude of socioeconomic inequalities in edentulism.</div></div><div><h3>Methods</h3><div>The Lancet Commission on Oral Health gathered and analysed nationally representative available data from 40 high, middle- and low-income countries, collected between 2007 and 2018. The study included 117,397 individuals 20 years or older. The outcome was edentulism, defined as the absence of all natural teeth. We categorised countries into seven welfare regimes, which served as both the primary exposure and an effect modifier. Individual-level variables included sex, age and a composite measure of socioeconomic position: “wealth” measured in quintiles. Inverse probability of treatment weight and multilevel logistic regression were employed to estimate the odds of being edentulous, and cross–level interaction terms between wealth and country factors.</div></div><div><h3>Findings</h3><div>Individuals at the lowest wealth quintile had the highest prevalence of edentulism in all regimes. The highest age-sex standardised prevalence was found in Eastern European countries (8.4%, 95% Confidence Interval: 7.6–9.3), followed by Corporative (8.1%, 95% CI: 7.0–9.3), while the lowest was among the Insecurity regime (0.8%, 95% CI: 0.4–1.5), followed by the Scandinavian regime (4.7%, 95% CI: 3.5–6.1). Liberal countries presented the highest magnitude of absolute and relative inequalities, where the lowest quintile had OR = 20.6 (95% CI: 15.3–27.8) times higher likelihood of being edentulous and 17.3 percentage points (pp) higher prevalence. Low-income countries in the Insecurity regime presented the lowest level of inequality. Among high- and upper-middle income countries, the Scandinavian regime had the lowest absolute inequalities (5.5 pp difference between highest and lowest quintiles). The Informal Security regime had the lowest relative differences between the highest and lowest quintiles (OR = 2.20, 95% CI: 1.06–4.59).</div></div><div><h3>Interpretation</h3><div>Our findings indicate that some welfare regime policies may enhance oral health while decreasing socioeconomic inequalities. Higher prevalence and inequalities among industrialised countries may reflect higher levels of oral health hazards.</div></div><div><h3>Funding</h3><div>This was partially supported by a <span>National Institute for Health and Care Research</span> (UK) grant number <span><span>132731</span></span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101578"},"PeriodicalIF":13.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145847659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis—leave no one behind: author's reply","authors":"Jeffrey V. Lazarus ,&nbsp;William Alazawi ,&nbsp;Christopher D. Byrne ,&nbsp;Cyrielle Caussy ,&nbsp;Paul N. Brennan","doi":"10.1016/j.lanepe.2025.101575","DOIUrl":"10.1016/j.lanepe.2025.101575","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"60 ","pages":"Article 101575"},"PeriodicalIF":13.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}